Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7706)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Oct 21, 2022 (publication date) through Aug 28, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Weingarden AR, Gubatan J, Singh S, Balabanis TC, Patel A, Sharma A, Habtezion A. Immune checkpoint inhibitor-mediated colitis is associated with cancer overall survival. World J Gastroenterol 2022; 28(39): 5750-5763 [PMID: 36338892 DOI: 10.3748/wjg.v28.i39.5750] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v28/i39/5750.htm |
| Number | Citing Articles |
| 1 |
Jiayang Yu, Yufei Zhang, Chun-Guang Wang, Wei Yang, Fen Chen. Associations between immune-related adverse events and the effectiveness of immunotherapeutic agents in advanced melanoma: A systematic review and meta-analysis. Dermatologica Sinica 2025; 43(2): 107 doi: 10.4103/ds.DS-D-24-00059
|
| 2 |
Tae Kyun Kim, Hyun Seok Lee, Eun Soo Kim. Incidence and risk factors of immune checkpoint inhibitor-induced colitis in Korean patients with cancer. The Korean Journal of Internal Medicine 2025; 40(1): 49 doi: 10.3904/kjim.2024.135
|
| 3 |
Masaya Iwamuro, Sakiko Hiraoka, Motoyuki Otsuka. A case of immune checkpoint inhibitor-associated colitis treated with infliximab. Okayama Igakkai Zasshi (Journal of Okayama Medical Association) 2024; 136(2): 69 doi: 10.4044/joma.136.69
|
| 4 |
Shoichiro Hirata, Yoshiyasu Kono, Emi Tanaka, Masahiko Sue, Yasuto Takeuchi, Tomoki Yoshikawa, Yoshie Maki, Tomohiro Kamio, Daisuke Kametaka, Katsunori Matsueda, Chihiro Sakaguchi, Kenta Hamada, Masaya Iwamuro, Seiji Kawano, Yoshiro Kawahara, Motoyuki Otsuka. Prognostic Impact of Gastrointestinal Immune-Related Adverse Events Depends on Nutritional Status in Cancer Patients Treated with Immune Checkpoint Inhibitors. Cancers 2025; 17(16): 2634 doi: 10.3390/cancers17162634
|
| 5 |
Kristian C. Williams, Abigail Gault, Amy E. Anderson, Christopher J. Stewart, Christopher A. Lamb, R. Ally Speight, Neil Rajan, Ruth Plummer, Arthur G. Pratt. Immune-related adverse events in checkpoint blockade: Observations from human tissue and therapeutic considerations. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1122430
|
| 6 |
Gonzalo Durán-Pacheco, G Scott Chandler, Vidya Maiya, Mark A Socinski, Guru Sonpavde, Javier Puente, Laurent Essioux, Corey Carter, Jose Vicente Cardona, Rajat Mohindra, Jarushka Naidoo. Correlation of safety and efficacy of atezolizumab therapy across indications. Journal for ImmunoTherapy of Cancer 2024; 12(11): e010158 doi: 10.1136/jitc-2024-010158
|
| 7 |
Anas Zaher, Maria Julia Moura Nascimento Santos, Hassan Elsaygh, Stephen J. Peterson, Carolina Colli Cruz, Anusha Shirwaikar Thomas, Yinghong Wang. Management of refractory checkpoint inhibitor-induced colitis. Expert Opinion on Drug Safety 2025; : 1 doi: 10.1080/14740338.2025.2496431
|